**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 57206

**Manuscript Type:** META-ANALYSIS

**Efficacy of pancreatoscopy for pancreatic duct stones: A systematic review and meta-analysis**

Saghir SM *et al*. Pancreatoscopy for pancreatic duct stones: A meta-analysis

Syed M Saghir, Harmeet S Mashiana, Babu P Mohan, Banreet S Dhindsa, Amaninder Dhaliwal, Saurabh Chandan, Neil Bhogal, Ishfaq Bhat, Shailender Singh, Douglas G Adler

**Syed M Saghir, Banreet S Dhindsa,** Department of Internal Medicine, University of Nevada Las Vegas School of Medicine, Las Vegas, NV 89102, United States

**Harmeet S Mashiana, Amaninder Dhaliwal, Saurabh Chandan, Neil Bhogal, Ishfaq Bhat, Shailender Singh,** Division of Gastroenterology and Hepatology, University of Nebraska School of Medicine, Omaha, NE 68198-2000, United States

**Babu P Mohan, Douglas G Adler,** Division of Gastroenterology and Hepatology, University of Utah Health, Salt Lake City, UT 84132, United States

**Author contributions:** Saghir SM, Mashiana HS and Mohan BP contributed to analysis and interpretation of data; Saghir SM and Mashiana HS contributed to drafting the article; Mashiana HS, Dhindsa BS, Dhaliwal A and Bhogal N contributed to acquisition of data; Chandan S, Bhat I and Adler DG contributed to critical revision; Mashiana HS, Singh S and Adler DG contributed to final approval.

**Corresponding author: Douglas G Adler, FACG, FASGE, MD, Professor,** Division of Gastroenterology and Hepatology, University of Utah Health, 50 N Medical Dr., Salt Lake City, UT 84132, United States. douglas.adler@hsc.utah.edu

**Received:** May 28, 2020

**Revised:** June 29, 2020

**Accepted:** August 21, 2020

**Published online:** September 14, 2020

**Abstract**

BACKGROUND

Pancreatic duct stones can lead to significant abdominal pain for patients. Per oral pancreatoscopy (POP)-guided intracorporal lithotripsy is being increasingly used for the management of main pancreatic duct calculi (PDC) in chronic pancreatitis. POP uses two techniques: Electrohydraulic lithotripsy (EHL) and laser lithotripsy (LL). Data on the safety and efficacy are limited for this procedure. We performed a systematic review and meta-analysis with a primary aim to calculate the pooled technical and clinical success rates of POP. The secondary aim was to assess pooled rates of technical success, clinical success for the two individual techniques, and adverse event rates.

AIM

To perform a systematic review and meta-analysis of POP, EHL and LL for management of PDC in chronic pancreatitis.

METHODS

We conducted a comprehensive search of multiple electronic databases and conference proceedings including PubMed, EMBASE, Cochrane, Google Scholar and Web of Science databases (from 1999 to October 2019) to identify studies with patient age greater than 17 and any gender that reported on outcomes of POP, EHL and LL. The primary outcome assessed involved the pooled technical success and clinical success rate of POP. The secondary outcome included the pooled technical success and clinical success rate for EHL and LL. We also assessed the pooled rate of adverse events for POP, EHL and LL including a subgroup analysis for the rate of adverse event subtypes for POP: hemorrhage, post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP), perforation, abdominal pain, fever and infections. Technical success was defined as the rate of clearing pancreatic duct stones and clinical success as the improvement in pain. Random-effects model was used for analysis. Heterogeneity between study-specific estimates was calculated using the Cochran *Q* statistical test and *I*2 statistics. Publication bias was ascertained, qualitatively by visual inspection of funnel plot and quantitatively by the Egger test.

RESULTS

A total of 16 studies including 383 patients met the inclusion criteria. The technical success rate of POP was 76.4% (95%CI: 65.9-84.5; *I*2 = 64%) and clinical success rate was 76.8% (95%CI: 65.2-85.4; *I*2 = 66%). The technical success rate of EHL was 70.3% (95%CI: 57.8-80.3; *I*2 = 36%) and clinical success rate of EHL was 66.5% (95%CI: 55.2-76.2; *I*2 = 19%). The technical success rate of LL was 89.3% (95%CI: 70.5-96.7; *I*2 = 70%) and clinical success rate of LL was 88.2% (95%CI: 66.4-96.6; *I*2 = 77%). The incidence of pooled adverse events for POP was 14.9% (95%CI: 9.2-23.2; *I*2 = 49%), for EHL was 11.2% (95%CI: 5.9-20.3; *I*2 = 15%) and for LL was 13.1% (95%CI: 6.3-25.4; *I*2 = 31%). Subgroup analysis of adverse events showed rates of PEP at 7% (95%CI: 3.5-13.6; *I*2 = 38%), fever at 3.7% (95%CI: 2-6.9; *I*2 = 0), abdominal pain at 4.7% (95%CI: 2.7-7.8; *I*2 = 0), perforation at 4.3% (95%CI: 2.1-8.4; *I*2 = 0), hemorrhage at 3.4% (95%CI: 1.7-6.6; *I*2 = 0) and no mortality. There was evidence of publication bias based on funnel plot analysis and Egger’s test.

CONCLUSION

Our study highlights the high technical and clinical success rates for POP, EHL and LL. POP-guided lithotripsy could be a viable option for management of chronic pancreatitis with PDC.

**Key words:** Electrohydraulic shockwave lithotripsy; Laser lithotripsy; Chronic pancreatitis; Calculi; Extracorporeal shockwave lithotripsy; Endoscopic retrograde cholangiopancreatography; Systematic review; Meta-analysis; Outcome

Saghir SM, Mashiana HS, Mohan BP, Dhindsa BS, Dhaliwal A, Chandan S, Bhogal N, Bhat I, Singh S, Adler DG. Efficacy of pancreatoscopy for pancreatic duct stones: A systematic review and meta-analysis . *World J Gastroenterol* 2020; 26(34): 5207-5219

URL: https://www.wjgnet.com/1007-9327/full/v26/i34/5207.htm

DOI: https://dx.doi.org/10.3748/wjg.v26.i34.5207

**Core tip:** Current management for symptomatic pancreatic duct stones is extracorporeal shock wave lithotripsy (ESWL) or endoscopic retrograde cholangiopancreatography (ERCP) followed by surgery if the former is unsuccessful. Sparse data exists regarding safety and efficacy of per oral pancreatoscopy (POP)- guided lithotripsy. This is the first systematic review and meta-analysis evaluating safety and efficacy of POP using electrohydraulic lithotripsy and laser lithotripsy. The POP procedure is of interest compared to current standard of care due to the ability to directly visualize pancreatic duct calculi, perform lithotripsy and extract the stones in the same session. ESWL and ERCP require multiple sessions and have low technical success.

**INTRODUCTION**

Pancreatic duct (PD) stones are a common complication of chronic pancreatitis (CP), which can lead to obstruction of the PD and cause chronic abdominal pain and exocrine pancreatic insufficiency[1]. PD stones may be present in as many as 50%-90% of CP patients[1,2]. The cause of the pain is multifactorial, but is thought to be secondary to elevated pancreatic ductal pressures, elevated interstitial pancreatic pressure, ischemia, fibrosis, and inflammation-related injury to the nerves innervating the pancreas[1]. Relieving PD obstruction is an important aspect in treatment of patients with painful chronic pancreatitis.

Current management of symptomatic PD stones includes medical therapy such as pancreatic enzyme replacement therapy (PERT), extracorporeal shock wave lithotripsy (ESWL) with or without endoscopic retrograde cholangiopancreatography (ERCP), ERCP with pancreatic sphincterotomy and either balloon or basket retrieval with stent placement, peroral pancreatoscopy and/or surgery[1,2]. According to the 2018 European Society of Gastrointestinal Endoscopy (ESGE) and the 2017 United European Gastroenterology (UEG) guidelines, ESWL is the first line approach for patients with painful PD stones who have failed in medical therapy and who have stones greater than 5 mm[3,4]. ERCP is recommended for stones less than 5 mm[4]. The American College of Gastroenterology (ACG) 2020 guidelines recommend ERCP/interventional endoscopic ultrasound (EUS) for PD stone management[5]. If these modalities are unsuccessful, pancreatic surgery should be considered[6,7].

Per oral pancreatoscopy (POP)-guided lithotripsy is being increasingly used for the management of main pancreatic duct calculi (PDC) in the setting of CP[2,8]. Previously two operators were required to do this procedure and imaging quality was poor, but with the advent of newer technology, POP by single operator is now widely available[9]. POP uses two techniques: electrohydraulic lithotripsy (EHL) and laser lithotripsy (LL). EHL technique uses a charge generator and bipolar probe to create a spark to produce a vapor plasma. The vapor plasma becomes a cavitation bubble that oscillates around the tip of the probe, which leads to stone fragmentation by absorption of rebounding shockwaves from the vapor. LL technique uses laser light at a specific wavelength to induce fragmentation[1]. Both techniques simply fragment stones into smaller pieces that still need to be removed *via* balloon and basket retrieval devices.

Information about the safety profile of POP and ESWL is limited. We performed a systematic review and meta-analysis on POP to assess the two techniques with regards to stone fragmentation, safety, and efficacy.

**MATERIALS AND METHODS**

***Literature search***

We conducted a comprehensive search of multiple electronic databases and conference proceedings including PubMed, EMBASE, Cochrane, Google Scholar, and Web of Science databases (from 1999 to October 2019). We identified studies reporting on outcomes of POP-guided intracorporal lithotripsy and followed the Preferred Reporting items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines[10]. The schematic diagram of study selection as per PRISMA guidelines is illustrated in Figure 1.

Literature search keywords included a combination of “per-oral”, “pancreatoscopy”, “pancreatoscope”, “POP”, “electrohydraulic”, “EHL”, “laser”, “lithotripsy”, “LL”, “pancreas”, “calculi”, “stones”, “chronic” and “pancreatitis”. The literature retrieved was restricted to studies done on humans and published in English. Two authors (BD, HS) independently evaluated titles and abstracts obtained from the literature search and discarded any studies that were irrelevant to our topic, based on predetermined inclusion and exclusion criteria. We then reviewed the complete versions of the articles of interest to determine if they contained relevant context. Any article with discrepancies was reviewed by a third author (SS).

Additional relevant articles were discovered from the bibliographic sections from the articles of interest.

***Study selection***

In this meta-analysis, studies that discussed the use of POP, EHL, and LL in patients with pancreatic duct stones were included. We included relevant studies for the data analysis regardless of their geographical location, inpatient/outpatient setting, or abstract/manuscript status.

The exclusion criteria included the following: (1) Alternative therapies for management of pancreatic duct stones other than POP; (2) use of POP for indications other than for pancreatic duct stones; (3) studies of the pediatric population (age < 17 years); and (4) studies published in languages other than English.

In instances where there were multiple articles from the same cohort or overlapping cohorts, we used the ones that were the most relevant, comprehensive and/or recent.

***Data extraction***

Information regarding study-related outcomes from the individual studies was extracted onto a standardized form by three authors (BD, HM, SMS).

***Risk of bias***

The collected data was evaluated akin to single group cohort studies and thus, we used the Newcastle-Ottawa scale to assess the quality of these studies[11]. Details of the scale is provided in Supplementary Table 1.

***Statistical analysis***

The pooled estimates were calculated with meta-analysis techniques as per DerSimonian and Laird using the random-effects model[12]. A continuity correction of 0.5 was added to the number of incident cases if incidence of an outcome was zero before statistical analysis[13]. Heterogeneity was evaluated *via* Cochrane *Q* statistical test for heterogeneity and the *I*2 statistics[14,15]. *I*2 values of < 30%, 30% to 60%, 61% to 75%, and > 75% were indicative of low, moderate, substantial, and significant heterogeneity, respectively[16]. Publication bias was determined quantitatively *via* the Egger test and qualitatively *via* visual inspection of the funnel plot[17]. With the presence of publication bias, we used the fail-safe N test and the Duval and Tweedie’s “Trim and Fill” test to determine the impact of the bias[18]. Impact was described in three levels based on similarities between the reported results and of those estimated as if there were no bias. Impact was classified as minimal if versions of both results were valued to be same, modest if there was substantial change in effect size, but the conclusion remained the same, or severe if the final conclusion of the analysis was subject to change by the bias[19].

All of our analyses were executed using comprehensive meta-analysis software, version 3 (BioStat, Englewood, NJ, United States).

***Outcomes assessed***

**Primary outcomes:** (1) Pooled technical success rate of POP-guided lithotripsy; and (2) Pooled clinical success rate of POP-guided lithotripsy.

**Secondary outcomes:** (1)Pooled technical success rate: EHL and LL; (2) Pooled clinical success rate: EHL and LL; (3) Pooled rate of adverse events (AE): POP, EHL and LL; and (4) Pooled rate of AE subtypes for POP: hemorrhage, post-ERCP pancreatitis (PEP), perforation, abdominal pain, fever and infections.

***Definition of outcomes***

Technical success rate was defined as the rate of clearing the pancreatic duct stones[2,7-9,20-31]. Clinical success was defined as improvement of the symptoms, primarily pain[2,7,20-26,28-31]. AE was defined as complications directly related to the procedure.

**RESULTS**

***Search results and characteristics of the population***

Our initial search yielded 361 results. There was a total of 16 studies that reported on POP lithotripsy procedures. Ten of these studies reported outcomes on POP using EHL[2,7-9,20,21,23,25,29,30] and 8 studies reported outcomes on POP using LL[2,20,21,24,26-28,31].

Ten of the 16 studies reported gender differences, with 65% of the population being male. The mean age reported in 9 of the 16 studies on POP was 54.4 years. The patient demographics are shown in Table 1.

***Characteristics and quality of included studies***

Nine studies were prospective, and the rest were retrospective. Eleven studies were from a single center and the remainder from multicenters. Twelve studies were in full text and 4 studies were in abstract form. There were no population-based studies. The clinical outcomes from all studies were adequately documented.

***Outcomes of the meta-analysis***

A total of 383 patients underwent 464 POP procedures. One hundred and forty-seven patients underwent 265 EHL procedures. One hundred and forty-two patients underwent 199 LL procedures.

***Primary outcomes***

The pooled technical success rate of POP was 76.4% (95%CI: 65.9-84.5; *I*2 = 64%) and the pooled clinical success rate of POP was 76.8% (95%CI: 65.2-85.4; *I*2 = 66%).Figure 2 shows the forest plots for technical and clinical success of POP, respectively.

***Secondary outcomes***

The pooled technical success rate of EHL was 70.3% (95%CI: 57.8-80.3; *I*2 = 36%) and the pooled technical success rate for LL was 89.3% (95%CI: 70.5-96.7; *I*2 = 70%). The pooled clinical success rate of EHL was 66.5% (95%CI: 55.2-76.2; *I*2 = 19%) and of LL was 88.2% (95%CI: 66.4-96.6; *I*2 = 77%). The pooled rates of technical success, clinical success, AE of POP, EHL and LL are presented in Table 2. The pooled POP AE rate was 14.9% (95%CI: 9.2-23.2; *I*2 = 49%), the pooled POP EHL AE rate was 11.2% (95%CI: 5.9-20.3; *I*2 = 15%) and the pooled POP LL AE rate was 13.1% (95%CI: 6.3-25.4; *I*2 = 31%). The subgroup analysis for POP AE were as follows: post-ERCP pancreatitis (PEP), 7% (95%CI: 3.5-13.6; *I*2 = 38%); fever, 3.7% (95%CI: 2-6.9; *I*2 = 0); abdominal pain, 4.7% (95%CI: 2.7-7.8; *I*2 = 0); perforation, 4.3% (95%CI: 2.1-8.4; *I*2 = 0); hemorrhage, 3.4% (95%CI: 1.7-6.6; *I*2 = 0) and no mortality. The AE in all procedures is shown in Table 3. Figures 3-5 show technical and clinical success of EHL, technical and clinical success of LL, and total adverse events, respectively.

***Validation of meta-analysis results***

**Sensitivity analysis**

We excluded one study at a time and explored its effect on the main summary evaluation to determine if any one study had a dominant effect on the meta-analysis. We concluded that there was no significant effect on the outcome or heterogeneity.

The subgroup analysis of technical and clinical success by geographical location (United States, Japan and Europe), publication type (manuscript/abstract), study center (single/multicenter), and study type (retrospective/prospective) did not reveal major differences.

**Heterogeneity**

Based on prediction interval and *I*2 analysis for heterogeneity, we assessed dispersion of the calculated rates. With *I*2 we can determine what proportion in terms of dispersion is true *vs* chance[32]. The technical success of POP, clinical success of POP and technical success of LL showed substantial heterogeneity. The technical success in EHL, POP AE, POP LL AE, and PEP showed moderate heterogeneity. Clinical success in EHL, POP EHL AE and remaining subgroup analysis of AE had low heterogeneity. Clinical success for LL had significant heterogeneity.

***Publication bias***

Based on the results of the funnel plot and Eggers regression test, there was publication bias. Further assessment using the fail-safe N test and the Duval and Tweedie’s “Trim and Fill” test did not affect the final pooled outcomes. Figure 6 shows the funnel plot.

**DISCUSSION**

Our study demonstrates that the technical success rate of POP was 76.4% and the clinical success rate was 76.8%. Eight out of 16 studies performed ESWL[2,21-23,26,29,30] and all studies attempted standard ERCP prior to POP. This highlights that POP-guided lithotripsy can be utilized when patients fail in the first-line therapy.

The overall technical success ranged from 37.5%-95% and this variability could be secondary to the type of POP procedure used and the experience of the individual operator. On indirect comparative analysis between EHL and LL, we found that LL had higher overall rates of technical and clinical success. This may be secondary to the ability of LL to fragment denser stones (*i.e.*, Hounsfield index > 2000 HU) as compared to EHL[2]. Although EHL is more widely available as compared to LL, LL tends to be much more expensive and requires special precautions compared with EHL. On subgroup analysis, studies with more than 20 patients showed higher technical success as compared to studies with less than 20 patients. This indicates that operator expertise may have influence on technical success.

Multiple stones, strictures, impacted stones, difficulty in cannulating PD due to angulation, poor visibility, equipment failure, or stones greater than 17 mm are other factors that may lead to lower technical success of POP[2,7,9,22-24,28-30]. Gutierrez *et al*[2] reported that presence of 3 or more stones was an independent risk factor for technical failure of POP (*P* < 0.04). Conversely, Han *et al*[22] reported that increased stone burden lead to higher technical success as these patients had higher chances of having smaller stones as compared to larger stones, which led to easier clearance.

Only Gerges *et al*[21] reported data regarding quality of life *via* questionnaires for pre- and post-procedure pain improvement based on a numeric rating scale decreased from mean of 5.4 ± 1.6 to 2.8 ± 1.8 (*P* < 0.01). Improvement in quality of life was reported by 89% of the patients in this study, which is comparable to ESWL[21,33].

The overall pooled AE rate of POP was comparable to ESWL ranging from 7% to 15%[34-37]. On subgroup analysis, the pooled AE rate of EHL and LL was similar at 11.2% and 13.1%, respectively. PEP was the most common AE and was comparable to ESWL at 7%[4,33,35].

Several limitations exist in our meta-analysis. Most of our studies were performed in tertiary care referral centers, so they may not be reflective of outcomes seen with less experienced operators. Also, POP does not reflect the skill of an average endoscopist. Our analysis contains studies that are retrospective in nature, which contribute to selection bias. No studies included data to compare POP as a first-line therapy with POP as a second-line therapy. Less than 5% of patients underwent POP as a first-line procedure and the individual outcomes were not mentioned in these studies. Nevertheless, this study contains the best available literature thus far with respect to POP. More studies are warranted to evaluate the technical and clinical success of EHL and LL. Clinical success is best defined universally with questionnaires, scores or scales to assess improvement of pain and quality of life, but not all studies provided this data.

**CONCLUSION**

In summary, POP-guided lithotripsy is a viable option for management of patients with chronic pancreatitis and symptomatic PD stones. We found LL technique to have a higher technical and clinical success rate with comparable AE rates. Optimal techniques for POP should be selected based on the clinical situation, device availability, and local center expertise. Further randomized controlled trials are needed for head to head comparison of the two techniques and evaluate if POP can be a potential first-line therapy in these cases.

**ARTICLE HIGHLIGHTS**

***Research background***

Painful chronic calcifying pancreatitis management involves pancreatic enzyme replacement therapy, extracorporeal shock wave lithotripsy (ESWL) with or without endoscopic retrograde cholangiopancreatography (ERCP), ERCP with pancreatic sphincterotomy and either balloon or basket retrieval with stent placement, peroral pancreatoscopy (POP) and/or surgery. POP utilizes two different methods for pancreatic stone lithotripsy, which are electrohydraulic lithotripsy (EHL) or laser lithotripsy (LL).

***Research motivation***

There are limited data regarding the safety and efficacy of POP for symptomatic pancreatic calculi.

***Research objectives***

We aimed to assess the safety and efficacy of both POP techniques in regard to stone fragmentation. Primary outcomes assessed involved technical and clinical success of POP. Secondary outcomes included technical and clinical success for EHL and LL, and adverse events (AE) for POP, EHL and LL.

***Research methods***

We conducted a comprehensive search of multiple electronic databases and conference proceedings including PubMed, EMBASE, Cochrane, Google Scholar and Web of Science databases. Statistical analysis was conducted *via* comprehensive meta-analysis software.

***Research results***

POP-guided lithotripsy was successful in patients who had failed in the first-line therapy. On indirect comparative analysis, LL was found to have higher technical and clinical success than EHL. POP AE was comparable to ESWL. The AE for EHL and LL was similar on indirect comparison. PEP was the most common AE and was comparable to ESWL.

***Research conclusions***

POP-guided lithotripsy is a viable option for management of patients with chronic pancreatitis and symptomatic PD stones. We found LL technique to have a higher technical and clinical success rate with comparable AE rates.

***Research perspectives***

Further randomized controlled trials are needed for head to head comparison of the two techniques and evaluate if POP can be a potential first line therapy in these cases.

**REFERENCES**

1 **Gerges C**, Pullmann D, Schneider M, Siersema P, van Geenen E, Neuhaus H, Beyna T. Pancreatoscopy in endoscopic treatment of pancreatic duct stones: a systematic review. *Minerva Chir* 2019; **74**: 334-347 [PMID: 30371042 DOI: 10.23736/S0026-4733.18.07932-4]

2 **Brewer Gutierrez OI**, Raijman I, Shah RJ, Elmunzer BJ, Webster GJM, Pleskow D, Sherman S, Sturgess RP, Sejpal DV, Ko C, Maurano A, Adler DG, Mullady DK, Strand DS, DiMaio CJ, Piraka C, Sharahia R, Dbouk MH, Han S, Spiceland CM, Bekkali NLH, Gabr M, Bick B, Dwyer LK, Han D, Buxbaum J, Zulli C, Cosgrove N, Wang AY, Carr-Locke D, Kerdsirichairat T, Aridi HD, Moran R, Shah S, Yang J, Sanaei O, Parsa N, Kumbhari V, Singh VK, Khashab MA. Safety and efficacy of digital single-operator pancreatoscopy for obstructing pancreatic ductal stones. *Endosc Int Open* 2019; **7**: E896-E903 [PMID: 31281875 DOI: 10.1055/a-0889-7743]

3 **Dominguez-Munoz JE**, Drewes AM, Lindkvist B, Ewald N, Czakó L, Rosendahl J, Löhr JM; HaPanEU/UEG Working Group. Recommendations from the United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis. *Pancreatology* 2018; **18**: 847-854 [PMID: 30344091 DOI: 10.1016/j.pan.2018.09.016]

4 **Dumonceau JM**, Delhaye M, Tringali A, Arvanitakis M, Sanchez-Yague A, Vaysse T, Aithal GP, Anderloni A, Bruno M, Cantú P, Devière J, Domínguez-Muñoz JE, Lekkerkerker S, Poley JW, Ramchandani M, Reddy N, van Hooft JE. Endoscopic treatment of chronic pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Updated August 2018. *Endoscopy* 2019; **51**: 179-193 [PMID: 30654394 DOI: 10.1055/a-0822-0832]

5 **Gardner TB**, Adler DG, Forsmark CE, Sauer BG, Taylor JR, Whitcomb DC. ACG Clinical Guideline: Chronic Pancreatitis. *Am J Gastroenterol* 2020; **115**: 322-339 [PMID: 32022720 DOI: 10.14309/ajg.0000000000000535]

6 **Attwell AR**, Brauer BC, Chen YK, Yen RD, Fukami N, Shah RJ. Endoscopic retrograde cholangiopancreatography with per oral pancreatoscopy for calcific chronic pancreatitis using endoscope and catheter-based pancreatoscopes: a 10-year single-center experience. *Pancreas* 2014; **43**: 268-274 [PMID: 24518507 DOI: 10.1097/MPA.0b013e3182965d81]

7 **Bekkali NL**, Murray S, Johnson GJ, Bandula S, Amin Z, Chapman MH, Pereira SP, Webster GJ. Pancreatoscopy-Directed Electrohydraulic Lithotripsy for Pancreatic Ductal Stones in Painful Chronic Pancreatitis Using SpyGlass. *Pancreas* 2017; **46**: 528-530 [PMID: 28196019 DOI: 10.1097/MPA.0000000000000790]

8 **Chen YK,** Tarnasky PR, Raijman I, Pleskow D, Shah RJ, Fortajada EL. Peroral Pancreatoscopy (PP) for Pancreatic Stone Therapy and Investigation of Susptected Pancreatic Lesions-First Human Experience Using the Spyglass Direct Visualization System (SDVS). Gastrointest Endosc 2008; 67: AB108 [DOI: 10.1016/j.gie.2008.03.145]

9 **Fishman DS**, Tarnasky PR, Patel SN, Raijman I. Management of pancreaticobiliary disease using a new intra-ductal endoscope: the Texas experience. *World J Gastroenterol* 2009; **15**: 1353-1358 [PMID: 19294765 DOI: 10.3748/wjg.15.1353]

10 **Moher D**, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* 2009; **151**: 264-269, W64 [PMID: 19622511 DOI: 10.7326/0003-4819-151-4-200908180-00135]

11 **Stang A**. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; **25**: 603-605 [PMID: 20652370 DOI: 10.1007/s10654-010-9491-z]

12 **DerSimonian R**, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; **7**: 177-188 [PMID: 3802833 DOI: 10.1016/0197-2456(86)90046-2]

13 **Sutton AJ,** Abrams KR, Jones DR, Jones DR, Sheldon TA, Song F. Methods for meta-analysis in medical research. Chichester: Wiley, 2000

14 **Higgins JP**, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; **327**: 557-560 [PMID: 12958120 DOI: 10.1136/bmj.327.7414.557]

15 **Kanwal F**, White D. "Systematic Reviews and Meta-analyses" in Clinical Gastroenterology and Hepatology. *Clin Gastroenterol Hepatol* 2012; **10**: 1184-1186 [PMID: 23000489 DOI: 10.1016/j.cgh.2012.09.019]

16 **Guyatt GH**, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-Coello P, Glasziou P, Jaeschke R, Akl EA, Norris S, Vist G, Dahm P, Shukla VK, Higgins J, Falck-Ytter Y, Schünemann HJ; GRADE Working Group. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. *J Clin Epidemiol* 2011; **64**: 1294-1302 [PMID: 21803546 DOI: 10.1016/j.jclinepi.2011.03.017]

17 **Easterbrook PJ**, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. *Lancet* 1991; **337**: 867-872 [PMID: 1672966 DOI: 10.1016/0140-6736(91)90201-y]

18 **Duval S**, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000; **56**: 455-463 [PMID: 10877304 DOI: 10.1111/j.0006-341x.2000.00455.x]

19 **Rothstein HR,** Sutton AJ, Borenstein M. Publication bias in meta-analysis: prevention, assessment and adjustments. Chichester: Wiley, 2005: 1-7

20 **Canena J**, Lopes L, Fernandes J, Alexandrino G, Lourenço L, Libânio D, Horta D, Giestas S, Reis J. Outcomes of Single-Operator Cholangioscopy-Guided Lithotripsy in Patients with Difficult Biliary and Pancreatic Stones. *GE Port J Gastroenterol* 2019; **26**: 105-113 [PMID: 30976615 DOI: 10.1159/000488508]

21 **Gerges C**, Pullmann D, Bahin F, Schneider M, Siersema PD, Neuhaus H, van Geenen EM, Beyna T. SpyGlass DS-guided lithotripsy for pancreatic duct stones in symptomatic treatment-refractory chronic calcifying pancreatitis. *Endosc Int Open* 2019; **7**: E99-E103 [PMID: 30705939 DOI: 10.1055/a-0808-4499]

22 **Han S**, Shah RJ, Brauer BC, Edmundowicz SA, Hammad HT, Wagh MS, Wani S, Attwell AR. A Comparison of Endoscopic Retrograde Pancreatography With or Without Pancreatoscopy for Removal of Pancreatic Duct Stones. *Pancreas* 2019; **48**: 690-697 [PMID: 31091217 DOI: 10.1097/MPA.0000000000001317]

23 **Ito K**, Igarashi Y, Okano N, Mimura T, Kishimoto Y, Hara S, Takuma K. Efficacy of combined endoscopic lithotomy and extracorporeal shock wave lithotripsy, and additional electrohydraulic lithotripsy using the SpyGlass direct visualization system or X-ray guided EHL as needed, for pancreatic lithiasis. *Biomed Res Int* 2014; **2014**: 732781 [PMID: 24999474 DOI: 10.1155/2014/732781]

24 **Malachias A,** Kypraios D, Theodoropoulos L, Hatzinicolaou S-L, Stavrinides S, Saribegioglou N, Dimitroulopoulos D, Tsamakidis K, Korkolis D, Xinopoulos D. Sa1498 Pancreatoscopy-Guided Laser Lithotripsy for Difficult Pancreatic Duct Stones. A Single Center Experience. Gastrointest Endosc 2016; 83: AB274 [DOI: 10.1016/j.gie.2016.03.414]

25 **Ogura T**, Okuda A, Imanishi M, Miyano A, Amano M, Nishioka N, Kamiyama R, Higuchi K. Electrohydraulic Lithotripsy for Pancreatic Duct Stones Under Digital Single-Operator Pancreatoscopy (with Video). *Dig Dis Sci* 2019; **64**: 1377-1382 [PMID: 30456448 DOI: 10.1007/s10620-018-5374-z]

26 **Shah RJ,** Attwell AR, Raijman I, Kahaleh M, Patel S. 577 Per Oral Pancreatoscopy With Intraductal Holmium Laser Lithotripsy for Treatment of Main Pancreatic Duct Calculi: A Multi-Center US Experience. Gastrointest Endosc 2012; 75: AB154 [DOI: 10.1016/j.gie.2012.04.097]

27 **Maydeo A**, Kwek BE, Bhandari S, Bapat M, Dhir V. Single-operator cholangioscopy-guided laser lithotripsy in patients with difficult biliary and pancreatic ductal stones (with videos). *Gastrointest Endosc* 2011; **74**: 1308-1314 [PMID: 22136776 DOI: 10.1016/j.gie.2011.08.047]

28 **Hirai T**, Goto H, Hirooka Y, Itoh A, Hashimoto S, Niwa Y, Hayakawa T. Pilot study of pancreatoscopic lithotripsy using a 5-fr instrument: selected patients may benefit. *Endoscopy* 2004; **36**: 212-216 [PMID: 14986218 DOI: 10.1055/s-2004-814250]

29 **Howell DA**, Dy RM, Hanson BL, Nezhad SF, Broaddus SB. Endoscopic treatment of pancreatic duct stones using a 10F pancreatoscope and electrohydraulic lithotripsy. *Gastrointest Endosc* 1999; **50**: 829-833 [PMID: 10570346 DOI: 10.1016/s0016-5107(99)70168-9]

30 **Brauer BC,** Jing T, Chen YK, Shah RJ. ERCP with pancreatoscopy and electrohydraulic lithotripsy (EHL) for calcific pancreatitis. Gastrointest Endosc 2007; 65: AB241 [DOI: 10.1016/j.gie.2007.03.540]

31 **Alatawi A**, Leblanc S, Vienne A, Pratico CA, Gaudric M, Duchmann JC, Boyer J, Mangialavori L, Chaussade S, Prat F. Pancreatoscopy-guided intracorporeal laser lithotripsy for difficult pancreatic duct stones: a case series with prospective follow-up (with video). *Gastrointest Endosc* 2013; **78**: 179-183 [PMID: 23540440 DOI: 10.1016/j.gie.2013.02.015]

32 **Mohan BP**, Adler DG. Heterogeneity in systematic review and meta-analysis: how to read between the numbers. *Gastrointest Endosc* 2019; **89**: 902-903 [PMID: 30902218 DOI: 10.1016/j.gie.2018.10.036]

33 **Moole H**, Jaeger A, Bechtold ML, Forcione D, Taneja D, Puli SR. Success of Extracorporeal Shock Wave Lithotripsy in Chronic Calcific Pancreatitis Management: A Meta-Analysis and Systematic Review. *Pancreas* 2016; **45**: 651-658 [PMID: 26580454 DOI: 10.1097/MPA.0000000000000512]

34 **Inui K**, Tazuma S, Yamaguchi T, Ohara H, Tsuji T, Miyagawa H, Igarashi Y, Nakamura Y, Atomi Y. Treatment of pancreatic stones with extracorporeal shock wave lithotripsy: results of a multicenter survey. *Pancreas* 2005; **30**: 26-30 [PMID: 15632696]

35 **Li BR**, Liao Z, Du TT, Ye B, Zou WB, Chen H, Ji JT, Zheng ZH, Hao JF, Jiang YY, Hu LH, Li ZS. Risk factors for complications of pancreatic extracorporeal shock wave lithotripsy. *Endoscopy* 2014; **46**: 1092-1100 [PMID: 25251205 DOI: 10.1055/s-0034-1377753]

36 **Haraldsson S**, Roug S, Nøjgaard C, Novovic S, Gluud LL, Feldager E, Schmidt PN. Extracorporeal shock wave lithotripsy for pancreatic duct stones: an observational study. *Scand J Gastroenterol* 2018; **53**: 1399-1403 [PMID: 30353766 DOI: 10.1080/00365521.2018.1508611]

37 **Li BR**, Liao Z, Du TT, Ye B, Chen H, Ji JT, Zheng ZH, Hao JF, Ning SB, Wang D, Lin JH, Hu LH, Li ZS. Extracorporeal shock wave lithotripsy is a safe and effective treatment for pancreatic stones coexisting with pancreatic pseudocysts. *Gastrointest Endosc* 2016; **84**: 69-78 [PMID: 26542375 DOI: 10.1016/j.gie.2015.10.026]

**Footnotes**

**Conflict-of-interest statement:** The authors deny any conflict of interest.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** May 28, 2020

**First decision:** June 12, 2020

**Article in press:** August 21, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Tierney J **S-Editor:** Ma YJ **L-Editor:** MedE-Ma **P-Editor:** Zhang YL

**Figure Legends**



**Figure 1 Study selection process in accordance with preferred reporting items for systematic reviews and meta-analysis statement.**

**A screenshot of a cell phone

Description automatically generated**

**A**

**A screenshot of a cell phone

Description automatically generated**

**B**

**Figure 2 per oral pancreatoscopy.** A: Forest plot for the technical success of per oral pancreatoscopy; B: Forest plot for the clinical success of per oral pancreatoscopy.

A screenshot of a cell phone

Description automatically generated

A

A screenshot of a cell phone

Description automatically generated

B

**Figure 3 electrohydraulic lithotripsy.** A: Forest plots showing technical success of electrohydraulic lithotripsy; B: Forest plots showing clinical success of electrohydraulic lithotripsy.

A screenshot of a cell phone

Description automatically generated

A

A screenshot of a cell phone

Description automatically generated

B

**Figure 4 Laser lithotripsy.** A: Forest plots showing technical success of laser lithotripsy; B: Forest plots showing clinical success of laser lithotripsy.

A screenshot of a cell phone

Description automatically generated

**Figure 5 Forest plots for adverse events.**

**A screenshot of a cell phone

Description automatically generated**

**Figure 6 Funnel plots for publication bias.**

**Table 1 Description of 16 studies included in the final analysis**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Type of study** | **Center** | **Mean age (yrs)** |  | **No. of patients** |  | **Males** | **Females** |
| **Total** | **EHL** | **LL** | **Total** | **Total** |
| Howell *et al*[29] | 1999 | Prospective | Single | 62.5 | 6 | 6 | 0 | 5 | 1 |
| Hirai *et al*[28] | 2004 | Prospective | Single | 51.2 | 17 | 0 | 17 | 9 | 8 |
| Brauer *et al*[30] | 2007 | Prospective | Single | 54 | 27 | 27 | 0 | 12 | 15 |
| Chen *et al*[8] | 2008 | Prospective | Single | -- | 10 | 10 | 0 | -- | -- |
| Fishman *et al*[9] | 2009 | Retrospective | Multi | -- | 6 | 6 | 0 | -- | -- |
| Maydeo *et al*[27] | 2011 | Prospective | Single | -- | 4 | 0 | 4 | -- | -- |
| Shah *et al*[26] | 2012 | Retrospective | Multi | 51 | 28 | 0 | 28 | -- | -- |
| Alatawi *et al*[31] | 2013 | Prospective | Single | 53.8 | 5 | 0 | 5 | 4 | 1 |
| Ito *et al*[23] | 2014 | Prospective | Single | -- | 8 | 8 | 0 | -- | -- |
| Malachias *et al*[24] | 2017 | Retrospective | Single | -- | 19 | 0 | 19 | 13 | 6 |
| Bekkali *et al*[7] | 2017 | Retrospective | Single | 45 | 6 | 6 | 0 | 3 | 3 |
| Canena *et al*[20] | 2019 | Prospective | Multi | -- | 3 | 2 | 1 | 3 | 0 |
| Gerges *et al*[21] | 2019 | Retrospective | Multi | 62.4 | 20 | 2 | 18 | 11 | 9 |
| Brewer Gutierrez *et al*[2] | 2019 | Retrospective | Multi | 54.7 | 109 | 59 | 50 | 77 | 32 |
| Ogura *et al*[25] | 2019 | Prospective | Single | 55 | 21 | 21 | 0 | 15 | 6 |
| Han *et al*[22] | 2019 | Retrospective | Single | -- | 94 | -- | -- | -- | -- |

EHL: Electrohydraulic lithotripsy; LL: laser lithotripsy.

**Table 2 Pooled rates of technical success, clinical success, and adverse events of per oral pancreatoscopy, electrohydraulic lithotripsy and laser lithotripsy**

|  |  |  |  |
| --- | --- | --- | --- |
|  | POP (%) | EHL (%) | LL (%) |
| Technical success | 76.4 (95%CI: 65.9-84.5; *I*2 = 64%) | 70.3 (95%CI: 57.8-80.3; *I*2 = 36%) | 89.3 (95%CI: 70.5-96.7; *I*2 = 70%) |
| Clinical success | 76.8 (95%CI: 65.2-85.4; *I*2 = 66%) | 66.5 (95%CI: 55.2-76.2; *I*2 = 19%) | 88.2 (95%CI: 66.4-96.6; *I*2 = 77%) |
| All adverse events | 14.9 (95%CI: 9.2-23.2; *I*2 = 49%) | 11.2 (95%CI: 5.9-20.3; *I*2 = 15%) | 13.1 (95%CI: 6.3-25.4; *I*2 = 31%) |
| PEP | 7.0 (95%CI: 3.5-13.6; *I*2 = 38%) | -- | -- |
| Fever | 3.7 (95%CI: 2-6.9; *I*2 = 0) | -- | -- |
| Abdominal pain | 4.7 (95%CI: 2.7-7.8; *I*2 = 0) | -- | -- |
| Perforation | 4.3 (95%CI: 2.1-8.4; *I*2 = 0) | -- | -- |
| Hemorrhage | 3.4 (95%CI: 1.7-6.6; *I*2 = 0) | -- | -- |

POP: Per oral pancreatoscopy; EHL: Electrohydraulic lithotripsy; LL: Laser lithotripsy; PEP: post-endoscopic retrograde cholangiopancreatography pancreatitis; abd: abdominal pain.

**Table 3 Adverse events in all procedures**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Total** | **PEP** | **Perforation** | **Bleeding** | **Fever** | **Abd pain** | **EHL** | **LL** |  |
| Howell *et al*[29] | 2 | 0 | 1 | 0 | 0 | 1 | 2 | 0 |  |
| Hirai *et al*[28] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |  |
| Brauer *et al*[30] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |  |
| Chen *et al*[8] | 1 | -- | -- | -- | -- | -- | 1 | -- |  |
| Fishman *et al*[9] | -- | -- | -- | -- | -- | -- | -- | -- |  |
| Maydeo *et al*[27] | -- | -- | -- | -- | -- | -- | -- | -- |  |
| Shah *et al*[26] | 7 | -- | -- | -- | -- | -- | 0 | 7 |  |
| Alatawi *et al*[31] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |  |
| Ito *et al*[23] | 2 | 1 | 1 | 0 | 0 | 0 | 2 | 0 |  |
| Malachias *et al*[24] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |  |
| Bekkali *et al*[7] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -- |  |
| Canena *et al*[20] | 2 | 1 | 0 | 0 | 1 | 0 | -- | -- |  |
| Gerges *et al*[21] | 7 | 5 | 1 | 1 | 0 | 0 | -- | -- |  |
| Brewer Gutierrez *et al*[2] | 14 | 5 | 1 | 2 | 3 | 3 | 5 | 6 |  |
| Ogura *et al*[25] | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |  |
| Han *et al*[22] | 8 | 1 | 0 | 0 | 1 | 5 | 7 | 1 |  |

PEP: post-endoscopic retrograde cholangiopancreatography pancreatitis; Abd: abdominal pain; EHL: Electrohydraulic lithotripsy; LL: Laser lithotripsy.